Cargando…
Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic?
This longitudinal analysis compares the prevalence of depressive symptoms in patients with psoriatic arthritis in the context of the COVID-19 pandemic. Data from a national patient register in Germany were analyzed regarding the Patient Health Questionnaire 2 (PHQ-2) to identify cases suspicious for...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591045/ https://www.ncbi.nlm.nih.gov/pubmed/34790678 http://dx.doi.org/10.3389/fmed.2021.748262 |
_version_ | 1784599129433833472 |
---|---|
author | Englbrecht, Matthias Bartz-Bazzanella, Peter von der Decken, Cay Gauler, Georg Wurth, Patrick Aries, Peer Karberg, Kirsten Kuhn, Christoph Schuch, Florian Späthling-Mestekemper, Susanna Vorbrüggen, Wolfgang Wendler, Jörg Welcker, Martin Kleinert, Stefan |
author_facet | Englbrecht, Matthias Bartz-Bazzanella, Peter von der Decken, Cay Gauler, Georg Wurth, Patrick Aries, Peer Karberg, Kirsten Kuhn, Christoph Schuch, Florian Späthling-Mestekemper, Susanna Vorbrüggen, Wolfgang Wendler, Jörg Welcker, Martin Kleinert, Stefan |
author_sort | Englbrecht, Matthias |
collection | PubMed |
description | This longitudinal analysis compares the prevalence of depressive symptoms in patients with psoriatic arthritis in the context of the COVID-19 pandemic. Data from a national patient register in Germany were analyzed regarding the Patient Health Questionnaire 2 (PHQ-2) to identify cases suspicious for depression at two time points, i.e., before and during the COVID-19 pandemic. Only patients with complete concurrent information on the Disease Activity in Psoriatic Arthritis Score (DAPSA) were included in the analysis. The frequency of depressive symptoms in psoriatic arthritis patients during the COVID-19 pandemic did not differ from the prevalence rates measured before. In addition, prevalence rates for depressive symptoms did not differ when stratifying the patient sample for DAPSA levels of disease activity measured before the pandemic. These results were confirmed further in a sensitivity analysis, limiting the second PHQ-2 assessment to lockdown periods only. However, longitudinal data on the prevalence of depressive symptoms in patients with rheumatic diseases, in general, and psoriatic arthritis, in particular, are scarce in the context of the COVID-19 pandemic. For a sensible comparison of prevalence rates for depressive symptoms in the future, underlying SARS-CoV-2 infection rates and resulting local healthcare disruptions need to be taken into account, besides the potential use of different depression screening tools to evaluate resulting numbers sensibly and draw corresponding conclusions for patient care. |
format | Online Article Text |
id | pubmed-8591045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85910452021-11-16 Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic? Englbrecht, Matthias Bartz-Bazzanella, Peter von der Decken, Cay Gauler, Georg Wurth, Patrick Aries, Peer Karberg, Kirsten Kuhn, Christoph Schuch, Florian Späthling-Mestekemper, Susanna Vorbrüggen, Wolfgang Wendler, Jörg Welcker, Martin Kleinert, Stefan Front Med (Lausanne) Medicine This longitudinal analysis compares the prevalence of depressive symptoms in patients with psoriatic arthritis in the context of the COVID-19 pandemic. Data from a national patient register in Germany were analyzed regarding the Patient Health Questionnaire 2 (PHQ-2) to identify cases suspicious for depression at two time points, i.e., before and during the COVID-19 pandemic. Only patients with complete concurrent information on the Disease Activity in Psoriatic Arthritis Score (DAPSA) were included in the analysis. The frequency of depressive symptoms in psoriatic arthritis patients during the COVID-19 pandemic did not differ from the prevalence rates measured before. In addition, prevalence rates for depressive symptoms did not differ when stratifying the patient sample for DAPSA levels of disease activity measured before the pandemic. These results were confirmed further in a sensitivity analysis, limiting the second PHQ-2 assessment to lockdown periods only. However, longitudinal data on the prevalence of depressive symptoms in patients with rheumatic diseases, in general, and psoriatic arthritis, in particular, are scarce in the context of the COVID-19 pandemic. For a sensible comparison of prevalence rates for depressive symptoms in the future, underlying SARS-CoV-2 infection rates and resulting local healthcare disruptions need to be taken into account, besides the potential use of different depression screening tools to evaluate resulting numbers sensibly and draw corresponding conclusions for patient care. Frontiers Media S.A. 2021-11-01 /pmc/articles/PMC8591045/ /pubmed/34790678 http://dx.doi.org/10.3389/fmed.2021.748262 Text en Copyright © 2021 Englbrecht, Bartz-Bazzanella, von der Decken, Gauler, Wurth, Aries, Karberg, Kuhn, Schuch, Späthling-Mestekemper, Vorbrüggen, Wendler, Welcker and Kleinert. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Englbrecht, Matthias Bartz-Bazzanella, Peter von der Decken, Cay Gauler, Georg Wurth, Patrick Aries, Peer Karberg, Kirsten Kuhn, Christoph Schuch, Florian Späthling-Mestekemper, Susanna Vorbrüggen, Wolfgang Wendler, Jörg Welcker, Martin Kleinert, Stefan Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic? |
title | Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic? |
title_full | Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic? |
title_fullStr | Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic? |
title_full_unstemmed | Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic? |
title_short | Prevalence of Depressive Symptoms in Patients With Psoriatic Arthritis: Have Numbers Changed During the COVID-19 Pandemic? |
title_sort | prevalence of depressive symptoms in patients with psoriatic arthritis: have numbers changed during the covid-19 pandemic? |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591045/ https://www.ncbi.nlm.nih.gov/pubmed/34790678 http://dx.doi.org/10.3389/fmed.2021.748262 |
work_keys_str_mv | AT englbrechtmatthias prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT bartzbazzanellapeter prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT vonderdeckencay prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT gaulergeorg prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT wurthpatrick prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT ariespeer prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT karbergkirsten prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT kuhnchristoph prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT schuchflorian prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT spathlingmestekempersusanna prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT vorbruggenwolfgang prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT wendlerjorg prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT welckermartin prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic AT kleinertstefan prevalenceofdepressivesymptomsinpatientswithpsoriaticarthritishavenumberschangedduringthecovid19pandemic |